An observational study in Coronary Artery Disease, sponsored by Seung-Jung Park. Recruiting at 42 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Seung-Jung Park · Observational
The purpose of this study is to observe clinical courses for long-term in patients with unprotected LMCA disease and to evaluate comparative results of medical treatment, coronary stenting with drug-eluting stents, and CABG for the treatment of an unprotected LMCA stenosis in the "real world" daily practice.
This study is a multicenter, large clinical registry to evaluate comparative outcomes of medical therapy, PCI with DES, or CABG for patients with unprotected LMCA stenosis in the Asia-Pacific, as recorded in the MAIN-IRIS Registry. Data will be prospectively collected on approximately 5000 subjects who diagnosed LM disease (>50% by visual estimation) at approximately 65 centers in Korea and Asia-Pacific region. Brief study design is as depicted in the following figure
4,857 studies on the registry are indexed under Coronary Artery Disease; 890 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 320 across 1,687 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Seung-Jung Park is the lead sponsor of 82 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive patients with unprotected LMCA diseases at participating centers will be evaluated for the entry into the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Significant unprotected left main stenosis (>50% by visual estimation)
Exclusion Criteria:
Consecutive patients with unprotected LMCA diseases at participating centers will be evaluated for the entry into the study.
Death
Time frame: 10-year
Cardiac death
Time frame: 10-year
Myocardial infarction
Time frame: 10-year
Cerebrovascular event
Time frame: 10-year
Target vessel revascularization
Time frame: 10-year
Target lesion revascularization
Time frame: 10-year
Stent thrombosis
According to Academic Research Consortium (ARC) criteria
Time frame: 10-year
Binary restenosis and late luminal loss in both in-stent and in-segment
Angiographic follow-up in the PCI group (as form of PCI substudy)
Time frame: 9-month
Rehospitalization
Time frame: 10-year
Composite event rate of death, myocardial infarction, Target Vessel Revascularization or cerebrovascular event
A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event that is considered to have occurred if any one of several different events is observed.
Time frame: 2-year
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No — This is not a publicly funded trial
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seung-Jung Park